Etubics Corporation, a biopharmaceutical company, develops prophylactic vaccines and immunotherapy products for the treatment of cancer, influenza, HIV, malaria, and hepatitis C virus. The company offers therapeutic vaccines for cancers, such as breast, colon, and head and neck cancers caused by HPV; and prophylactic vaccines for the treatment of infectious diseases, such as influenza, malaria, and HIV. It has a therapeutic vaccine product in pipeline that treats carcinoembryonic antigen expressing cancers, such as colorectal cancers. Etubics has developed a proprietary platform technology consisting of a next generation Ad5 vector vaccine platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Etubics Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers.
